NCT01413113View on ClinicalTrials.gov

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

October 31, 2015

Conditions
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid CancerStage IVB Follicular Thyroid CancerStage IVB Papillary Thyroid CancerStage IVC Follicular Thyroid CancerStage IVC Papillary Thyroid Cancer
Interventions
DRUG

pazopanib hydrochloride

Given PO

RADIATION

iodine I 131

Given IM

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Comprehensive Cancer Network

NETWORK

lead

University of Washington

OTHER

NCT01413113 - Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter